Glox Therapeutics
PrivateLast Round
Grant
Jan 21, 2025
Total Funding Raised
$7.24M
Company Overview
Glox Therapeutics operates in Healthcare & Life Sciences and is based in Glasgow. Its latest recorded funding round was a Grant round in January 2025.
Glox Therapeutics is a biotechnology company developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glox Therapeutics Comparables
Compare Glox Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DimiCare Biotech | 81% | |
| SNIPR Biome | 79% | |
| PrecisioBiotix Therapeutics | 77% |
For institutional investors. Book with your work email.
Glox Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 21, 2025 | ||||
| Grant | Nov 20, 2024 | ||||
| Seed | Nov 14, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Glox Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| PACE (Pathways to Antimicrobial Clinical Efficacy) | Grant |
| LifeArc | Grant |
| Boehringer Ingelheim Venture Fund | Seed |
| Scottish Investment Bank (Scottish Enterprise) | Seed |
| CF AMR Syndicate | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 19, 2025
Grew 63% QoQ, from 8 to 13 employees.
- Jun 6, 2025
Grew 50% QoQ, from 8 to 12 employees.
For institutional investors. Book with your work email.
Glox Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Glox Therapeutics's valuation, stock price, and market status.
Is Glox Therapeutics a public or private company?
Glox Therapeutics is a private company.
What is the current stock price of Glox Therapeutics?
Glox Therapeutics is a private company, so its shares have no public market price. Caplight tracks Glox Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Glox Therapeutics worth (valuation)?
Valuation information for Glox Therapeutics is not publicly available.
Can I buy Glox Therapeutics stock?
Glox Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Glox Therapeutics's last funding round?
Glox Therapeutics's most recent funding round was Grant on January 21, 2025.
Who are the main investors in Glox Therapeutics?
Key investors in Glox Therapeutics include Boehringer Ingelheim Venture Fund, Scottish Investment Bank (Scottish Enterprise).
Will Glox Therapeutics IPO soon?
No public IPO plans have been announced for Glox Therapeutics.
How can I track Glox Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Glox Therapeutics's shares on secondary markets.